The growing healthcare burden posed by hepatocellular carcinoma, the most common subtype of liver cancer, has prompted the ...

Learn about July 2025’s top biotech deals, featuring major collaborations in small molecules, antibodies, and drug delivery.

With thousands of press releases published each month, it can be difficult to keep up with everything on PR Newswire. To help ...

Sunshine Lake Pharma’s shares fell in their trading debut in Hong Kong, as the city’s buzz over first-day trading took a ...

The demand for treatments targeting myeloproliferative disorders is rising sharply, propelled by several key factors that underscore the market's rob ...

Out-licensing drugs to multinational corporations is a natural step for Chinese biotechs, but the recent rise in deals is ...

These 10 stocks could mint the next wave of millionaires › IDEAYA Biosciences (NASDAQ:IDYA), a precision oncology company focused on developing targeted therapies for cancer, reported its ...

In July 2025, Clinuvel Inc. conducted a CUV105 study will assess the efficacy and safety of afamelanotide and NB-UVB light in ...

IDEAYA Biosciences' clinical trial progress, strong financials, and diversified pipeline signal long-term growth potential ...

The neuroendocrine prostate cancer treatment space will experience significant changes during the forecast period of 2025–2034, owing to the launch o ...

As patent cliffs approach and new mechanisms gain ground, COPD drugs like HRS-9821 are fast becoming coveted assets.

Merck faces intense pressure from new global tariffs and a looming Keytruda patent expiration, but is fighting back with a $3 ...